摘要
目的:观察甲磺酸伊马替尼治疗慢性粒细胞白血病进展期患者的临床疗效。方法:选择31例慢性粒细胞白血病进展期患者,分为伊马替尼治疗组(治疗组12例)和对照组(19例),分别给予甲磺酸伊马替尼和联合化疗治疗,观察并比较2组间血液学有效率及不良反应耐受性等指标的变化。结果:治疗组总的血液学有效率为41.7%,对照组总的血液学有效率为5.3%,2组间比较差异有统计学意义(P<0.05)。治疗组患者药物不良反应发生率较对照组轻且容易耐受。结论:甲磺酸伊马替尼对进展期慢性粒细胞白血病患者有较好的疗效,且毒副反应轻,病人耐受性好。
Objective： To observe the efficacy of imatinib mesylate in the treatment of patients with chronic myeloid leukemia （CML） in advanced phase.. Methods： There were 31 patients in advanced CML phase were divided into two groups, one group（treatment group） was received imatinib therapy, the other was the historical control group（control group）were treated with combination chemotherapy and to compare the hematologic response and the tolerance of treatment toxity between the two groups. Results： Total hematologic response rate of imatinib treatment group was 41.7%. Total hematologic response rate of historical control group was 5. 3%. It was significantly lower than that of imatinib treatment group （P 〈0.05）. Toxicity of imatinib is not serious, and easy to tolerate. Conclusions： Imatinib mesylate demonstrates better therapeutic effect in the treatment of CML in advanced phase than traditional chemotherapy with comparatively mild toxity, patients have a good tolerance to imatinib.
出处
《新疆医科大学学报》
CAS
2008年第10期1366-1368,共3页
Journal of Xinjiang Medical University
